Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF3R | Q99062 | 2/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 15/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19262623 | 0.71 | CSF3R (0.34) | CSF3R | |
| SCHEMBL2208586 | 0.70 | PPARG (0.47) | CSF3R | |
| SCHEMBL29818702 | 0.70 | PPARG (0.47) | CSF3R | |
| SCHEMBL2207505 | 0.70 | CSF3R (0.48) | CSF3R | |
| SCHEMBL20682472 | 0.67 | PTGES (0.36) | — | |
| SCHEMBL20332193 | 0.66 | MCHR1 (0.37) | CSF3RHTTCYP2C9 | |
| SCHEMBL26922790 | 0.65 | TAAR1 (0.56) | HTT | |
| SCHEMBL20682471 | 0.64 | BRD4 (0.32) | LTB4RLTB4R2 | |
| SCHEMBL3964539 | 0.64 | TAAR1 (0.45) | CSF3R | |
| SCHEMBL4569074 | 0.64 | PPARA (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2019-06-20 | — | — | US | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CSF3R 4033/4885LTB4R 177/4885LTB4R2 157/4885 |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | CSF3R 4033/4885LTB4R 177/4885LTB4R2 157/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CSF3R 4033/4885LTB4R 177/4885LTB4R2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.